Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment.

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to a Radiopharmaceutical Therapy Trials with Dosimetry session. Dr.

ASCO 2025 circulating and tumor microenvironment determinants of patient response in the Checkmate 9ER trial, nivolumab and cabozantinib in advanced renal cell carcinoma (RCC).

In part four, Alan Wein concludes his discussion with Craig Comiter about male incontinence treatment preferences. Dr. Comiter's approach is severity-based: transobturator AdVance sling for mild ...

SNMMI 2025, post-177Lu therapy, WB SPECT/CT, WB SPECT/CT Studies Post Lu 177 Therapy, 177Lu-PSMA SPECT, StarGuide scanner, 177Lu-PSMA-617 radiopharmaceutical therapy.